Fentanyl is an opioid pain medication that is 100 times more powerful than morphine. It is used to treat patients
suffering from moderate to severe chronic pain. The patch is most often prescribed
for people with cancer. The fentanyl
transdermal patch was approved by
the Food & Drug Administration
(FDA) in 1990 for people with persistent to moderate severe pain.
The
Sandoz
fentanyl patch is manufactured by Johnson & Johnson and
its subsidiary Alza
Corporation. Sandoz is a transdermal patch that has
a reservoir containing a 3-day dose of fentanyl gel. The FDA has received
hundreds of reports of fatalities linked to Sandoz fentanyl patch use. The
cause of these deaths can be due to seal breaches allowing fentanyl gel to
leak from the patch, known as the “fold-over defect,” malfunction
of the rate control membrane or other defects.
Patients and caregivers who
come in contact with a leaking patch may experience severe side effects,
or potentially be victims of a fatal overdose. In addition to reports of
leaking patches, the FDA has investigated deaths and life-threatening side
effects in patients who never should have been prescribed the patch. In December
2007, reports of improper prescribing of the patch prompted the FDA
to issue its second Public Health Advisory regarding fentanyl pain patches,
which stated that "reports indicate that doctors have inappropriately
prescribed the fentanyl patch to patients for acute pain following surgery,
for headaches, occasional or mild pain, and other indications for which a
fentanyl patch should not be prescribed."
The FDA’s warning to
doctors and patients on the symptoms of fentanyl overdose included the following:
• Trouble with breathing, or slow or shallow breathing
• Slow heartbeat
• Severe sleepiness
• Cold, clammy skin
• Trouble with walking or talking
• Feeling faint, dizzy, or confused
According to the FDA, patients using
the fentanyl patch who experience those symptoms should get medical attention
right away. Additionally, patients or caregivers should call the patient's doctor
immediately if the patient's temperature exceeds 102 degrees while wearing a
fentanyl patch.
Heygood, Orr, Reyes, Pearson & Bartolomei is the leading law firm in
litigation involving fentanyl transdermal pain patches. On June 19, 2007,
a $5.5 million jury
verdict was awarded in a case against Johnson & Johnson and its subsidiary,
Alza Corporation, the manufacturers of the Duragesic fentanyl transdermal
pain patch. This case, the first Federal trial involving the Duragesic fentanyl
patch, was tried in the Federal District Court for the Southern District
of Florida, West Palm Beach Division. The verdict was achieved for the family
of a 28-year-old Florida man (Adam Hendelson) who died while wearing a Duragesic
fentanyl drug patch.
If you or a loved one has suffered injury, or a family member has died as
a result of using any brand of fentanyl transdermal pain patch, please fill
out our case review form to the right of this page for a free consultation.
DURAGESIC AND SANDOZ RECALLS:
On February, 12th, 2008, all 25-microgram-per-hour
patches that expire on or before December, 2009 sold in the U.S. were recalled by
Johnson & Johnson. The recall includes Duragesic and Sandoz brands, both
of which are manufactured by the Johnson & Johnson subsidiary Alza Corporation.
This recall follows a 2004
recall of five lots of 75-microgram-per-hour patches for leaking defects. Many other lots, of all sizes, that were not recalled
suffered from leak defects as well.
COMPLETE RECALLS & WARNINGS
ARCHIVE>>
DURAGESIC TRIAL NEWS ARTICLES:
7/10/07 - The Legal Broadcast Network – Civil Action Radio Features Interview with Trial Team on
Duragesic Fentanyl Patch $5.5M Verdict
6/19/07
- Bloomberg.com – J&J
Units Ordered to Pay $5.5 Million in Patch Case
6/19/07 - MedaNews.com – Heygood,
Orr, Reyes & Bartolomei
and Gulas & Stuckey: $5.5 Million Award in First
Federal Fentanyl Patch Trial
6/19/07 - Forbes.com –
Jury Awards $5.5M in Drug Patch Case
6/19/07 - NYTimes.com –
Companies Lose Drug Patch Suit
COMPLETE DURAGESIC
TRIAL ARCHIVE>>
Actavis Recalls Certain Fentanyl Patches
in the US as Precaution
2/17/08 - Actavis, Inc. Press Release
Read the article...
PRICARA™ Recalls 25 mcg/hr Duragesic® (fentanyl
transdermal system) CII Pain Patches
2/12/08 - Johnson & Johnson Press Release
Read the article...
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
Read the article...
$5.5 Million Award in First Federal Fentanyl Patch Trial
6/19/07 - PRNewsWire
Read the article...
Jury Deciding if Pain Patch Leaked, Killing
Man, 28
6/19/07 - Palm Beach Post
Read the article...